General Information of Drug Transporter (DT)
DT ID	DTD0061 Transporter Info
Gene Name	ABCC8
Protein Name	Sulfonylurea receptor 1
Gene ID	6833
UniProt ID	Q09428
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs757110
Site of GPD	chr11:17396930 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	C=0.2736/1370 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:         20 Drugs in Total
Glibenclamide	Drug Info	Diabetes Mellitus	Irrelevant to the decreased hemoglobin levels in patients (compare with Allele A)		[ 1]
Glimepiride	Drug Info	Diabetes Mellitus	Irrelevant to the decreased hemoglobin levels in patients (compare with Allele A)		[ 1]
Glipizide	Drug Info	Diabetes Mellitus	Irrelevant to the decreased hemoglobin levels in patients (compare with Allele A)		[ 1]
Gliclazide	Drug Info	Diabetes Mellitus	Irrelevant to the decreased hemoglobin levels in patients (compare with Allele A)		[ 1]
Gliquidone	Drug Info	Diabetes Mellitus	Irrelevant to the decreased hemoglobin levels in patients (compare with Allele A)		[ 1]
Glimepiride	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele A.		[ 2]
Glyburide	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele A.		[ 2]
Sulfonamides, Urea Derivatives	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele A.		[ 2]
Gliclazide	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele A.		[ 1]
Glimepiride	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele A.		[ 1]
Glipizide	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele A.		[ 1]
Gliquidone	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele A.		[ 1]
Glyburide	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele A.		[ 1]
Gliclazide	N.A.	Hypoglycemia	Allele C is not associated with decreased hemoglobin levels when exposed to glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele A.		[ 1]
Glimepiride	N.A.	Hypoglycemia	Allele C is not associated with decreased hemoglobin levels when exposed to glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele A.		[ 1]
Glipizide	N.A.	Hypoglycemia	Allele C is not associated with decreased hemoglobin levels when exposed to glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele A.		[ 1]
Gliquidone	N.A.	Hypoglycemia	Allele C is not associated with decreased hemoglobin levels when exposed to glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele A.		[ 1]
Glyburide	N.A.	Hypoglycemia	Allele C is not associated with decreased hemoglobin levels when exposed to glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele A.		[ 1]
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele C is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele A.		[ 3]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus	Allele C is not associated with decreased hemoglobin levels when exposed to glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele A.		[ 1]
Genotypes AA + CC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Sulfonamides	Drug Info	Diabetes Mellitus	Correlated with the increased drug response in patients (compare with genotype AC)		[ 4]
Sulfonamides, Urea Derivatives	N.A.	Hypoglycemia	Genotypes AA + CC is associated with increased response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to genotype AC.		[ 4]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus	Genotypes AA + CC is associated with increased response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to genotype AC.		[ 4]
Urea derivatives	N.A.	Diabetes Mellitus	Correlated with the increased drug response in patients (compare with genotype AC)		[ 4]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Sulfonamides, Urea Derivatives	N.A.	Hypoglycemia	Allele A is not associated with increased likelihood of Hypoglycemia when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 5]
Glimepiride	N.A.	Hypoglycemia	Allele A is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 6]
Glipizide	N.A.	Hypoglycemia	Allele A is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 6]
Glyburide	N.A.	Hypoglycemia	Allele A is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 6]
Glimepiride	N.A.	Hypoglycemia	Allele A is not associated with increased risk of Hypoglycemia when treated with glibenclamide and glimepiride in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 7]
Glyburide	N.A.	Hypoglycemia	Allele A is not associated with increased risk of Hypoglycemia when treated with glibenclamide and glimepiride in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 7]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Gliclazide	N.A.	Treatment Failure	Genotype CC is associated with increased likelihood of treatment failure when treated with glibenclamide or gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + AC.		[ 8]
Glyburide	N.A.	Treatment Failure	Genotype CC is associated with increased likelihood of treatment failure when treated with glibenclamide or gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + AC.		[ 8]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus	Patients with the CC genotype and diabetes mellitus may have an improved response to sulfonylureas as compared to the AC genotype. However, another study did not find any association between this variant and response to sulfonylureas. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.		[ 1]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus	Patients with the AA genotype and diabetes mellitus may have an improved response to sulfonylureas as compared to the AC genotype. However, another study did not find any association between this variant and response to sulfonylureas. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.		[ 1]
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus	Patients with the AC genotype and diabetes mellitus may have a worse response to sulfonylureas as compared to the AA and CC genotypes. However, another study did not find any association between this variant and response to sulfonylureas. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.		[ 1]
Genetic Polymorphism	rs2237991
Site of GPD	chr11:17418682 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.5520/1092 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tacrolimus	N.A.	Treatment Failure	Allele A is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.		[ 9]
Genetic Polymorphism	rs5219
Site of GPD	chr11:17388025 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C / T>G
Minor Allele Frequency	T=0.2600/514 (Global)
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Metformin	N.A.	Treatment Failure	Genotypes CT + TT is associated with increased clinical benefit to metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype CC.		[ 10]
Sulfonamides, Urea Derivatives	N.A.	Treatment Failure	Genotypes CT + TT is associated with increased clinical benefit to metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype CC.		[ 10]
Gliclazide	N.A.	Diarrhea	Genotypes CT + TT are associated with increased efficacy as measured by decrease in HbA1c when treated with gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.		[ 11]
Sulfonamides, Urea Derivatives	N.A.	Diarrhea	Genotypes CT + TT are associated with increased efficacy as measured by decrease in HbA1c after 6-month treatment when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype CC.		[ 11]
Tacrolimus	N.A.	Diabetes Mellitus, Type 2	Genotypes CT + TT is associated with increased risk of Diabetes Mellitus, Type 2 when treated with tacrolimus in people with heart transplantation or Kidney Transplantation as compared to genotype CC.		[ 12]
Gliclazide	N.A.	Diabetes Mellitus	Genotypes CT + TT are associated with increased efficacy as measured by decrease in HbA1c when treated with gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.		[ 11]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus	Genotypes CT + TT are associated with increased efficacy as measured by decrease in HbA1c after 6-month treatment when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype CC.		[ 11]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus, Type 2	Genotypes CT + TT are associated with increased efficacy as measured by decrease in HbA1c after 6-month treatment when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype CC.		[ 11]
Allele C	Click to Show/Hide the Full List of Affected Drugs:         15 Drugs in Total
Glimepiride	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele T.		[ 6]
Glipizide	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele T.		[ 6]
Glyburide	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele T.		[ 6]
Gliclazide	N.A.	Diarrhea	Allele C is not associated with dose of glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.		[ 1]
Glimepiride	N.A.	Diarrhea	Allele C is not associated with dose of glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.		[ 1]
Glipizide	N.A.	Diarrhea	Allele C is not associated with dose of glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.		[ 1]
Gliquidone	N.A.	Diarrhea	Allele C is not associated with dose of glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.		[ 1]
Glyburide	N.A.	Diarrhea	Allele C is not associated with dose of glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.		[ 1]
Gliclazide	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.		[ 1]
Glimepiride	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.		[ 1]
Glipizide	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.		[ 1]
Gliquidone	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.		[ 1]
Glyburide	N.A.	Hypoglycemia	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.		[ 1]
Sulfonamides, Urea Derivatives	N.A.	Hypoglycemia	Allele C is not associated with increased likelihood of Hypoglycemia when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele T.		[ 5]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus, Type 2	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.		[ 1]
Allele T	Click to Show/Hide the Full List of Affected Drugs:         11 Drugs in Total
Sulfonamides, Urea Derivatives	N.A.	Diarrhea	Allele T is not associated with decreased response to sulfonamides, urea derivatives.		[ 13]
Tolbutamide	N.A.	Diarrhea	Allele T is not associated with activity of KCNJ11 when treated with tolbutamide in xenopus oocytes.		[ 14]
Repaglinide	N.A.	Hypoglycemia	Allele T is associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.		[ 15]
Metformin	N.A.	Diabetes Mellitus, Type 2	Allele T is associated with increased likelihood of treatment failure when treated with metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 16]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus, Type 2	Allele T is associated with increased likelihood of treatment failure when treated with metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 16]
Glyburide	N.A.	Diabetes Mellitus, Type 2	Allele T is associated with decreased activity of KCNJ11 when treated with glibenclamide pancreatic islet cells.		[ 16]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus	Allele T is not associated with decreased response to sulfonamides, urea derivatives.		[ 13]
Repaglinide	N.A.	Diabetes Mellitus, Type 2	Allele T is associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.		[ 15]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus, Type 2	Allele T is not associated with decreased response to sulfonamides, urea derivatives.		[ 13]
Metformin	N.A.	Diabetes Mellitus, Type 2	Allele T is associated with increased likelihood of treatment failure when treated with metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 16]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus, Type 2	Allele T is associated with increased likelihood of treatment failure when treated with metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 16]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           9 Drugs in Total
Sulfonamides, Urea Derivatives	N.A.	Hypoglycemia	Genotype CT is associated with increased response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to genotypes CC + TT.		[ 4]
Gliclazide	N.A.	Diabetes Mellitus	Patients with diabetes mellitus and the CT genotype who are taking gliclazide may have improved response as compared to patients with the CC genotype and decreased response compared to the TT genotype. Other clinical and genetic factors may also influence response to gliclazide in patients with diabetes mellitus.		[ 11]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus	Genotype CT is associated with increased response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to genotypes CC + TT.		[ 4]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus	Patients with diabetes mellitus and the CT genotype who are taking sulfonylureas may have improved response as compared to patients with the CC genotype, although no association with response is also reported, and one found that this genotype had an improved response as compared to both homozygous genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.		[ 11]
Repaglinide	N.A.	Diabetes Mellitus, Type 2	Patients with the CT genotype are more likely to respond to repaglinide than patients with the CC genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.		[ 15]
Tacrolimus	N.A.	Diabetes Mellitus, Type 2	Patients with the CT genotype who are undergoing kidney or heart transplants may have an increased risk for developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the risk for developing NODAT.		[ 12]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus, Type 2	Patients with CT genotype and Type 2 diabetes may have better response (higher decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CC, or a poorer response (smaller decrease in HbA1c) as compared to patients with genotype TT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.		[ 11]
Metformin	N.A.	Diabetes Mellitus, Type 2	Patients with the CT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype or may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 16]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus, Type 2	Patients with the CT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype or may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 16]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:         10 Drugs in Total
Gliclazide	N.A.	Hypoglycemia	Genotype TT is associated with increased response to gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotypes CC + CT.		[ 17]
Gliclazide	N.A.	Diabetes Mellitus	Genotype TT is associated with increased response to gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotypes CC + CT.		[ 17]
Gliclazide	N.A.	Diabetes Mellitus	Patients with diabetes mellitus and the TT genotype who are taking gliclazide may have improved response as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to gliclazide in patients with diabetes mellitus.		[ 11]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus	Patients with diabetes mellitus and the TT genotype who are taking sulfonylureas may have improved response as compared to patients with the CC genotype, although no association with response is also reported, and one found that the heterozygous genotype had an improved response as compared to to both homozygous genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.		[ 11]
Repaglinide	N.A.	Diabetes Mellitus, Type 2	Patients with the TT genotype are more likely to respond to repaglinide than patients with the CC genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.		[ 15]
Tacrolimus	N.A.	Diabetes Mellitus, Type 2	Patients with the TT genotype who are undergoing kidney or heart transplants may have an increased risk for developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the risk for developing NODAT.		[ 12]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus, Type 2	Genotype TT is associated with increased response to gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotypes CC + CT.		[ 17]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus, Type 2	Patients with TT genotype and Type 2 diabetes may have better response (higher decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.		[ 11]
Metformin	N.A.	Diabetes Mellitus, Type 2	Patients with the TT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 16]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus, Type 2	Patients with the TT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 16]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Gliclazide	N.A.	Diabetes Mellitus	Patients with diabetes mellitus and the CC genotype who are taking gliclazide may have decreased response as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response to gliclazide in patients with diabetes mellitus.		[ 11]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus	Patients with diabetes mellitus and the CC genotype who are taking sulfonylureas may have worse response as compared to patients with the CT or TT genotypes, although no association with response is also reported, and one found that the heterozygous genotype had an improved response as compared to both homozygous genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.		[ 11]
Repaglinide	N.A.	Diabetes Mellitus, Type 2	Patients with the CC genotype are less likely to respond to repaglinide than patients with the CT or TT genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.		[ 15]
Tacrolimus	N.A.	Diabetes Mellitus, Type 2	Patients with the CC genotype who are undergoing kidney or heart transplants may have a decreased risk for developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the risk for developing NODAT.		[ 12]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus, Type 2	Patients with CC genotype and Type 2 diabetes may have a poorer response (smaller decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CT or TT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.		[ 11]
Metformin	N.A.	Diabetes Mellitus, Type 2	Patients with the CC genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 16]
Sulfonamides, Urea Derivatives	N.A.	Diabetes Mellitus, Type 2	Patients with the CC genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 16]
Genetic Polymorphism	rs1799859
Site of GPD	chr11:17397732 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.5910/1169 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Glimepiride	N.A.	Hypoglycemia	Allele T is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 6]
Glipizide	N.A.	Hypoglycemia	Allele T is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 6]
Glyburide	N.A.	Hypoglycemia	Allele T is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele C.		[ 6]
Genetic Polymorphism	rs1799854
Site of GPD	chr11:17427157 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.6360/1258 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Glimepiride	N.A.	Hypoglycemia	Allele A is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele G.		[ 6]
Glipizide	N.A.	Hypoglycemia	Allele A is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele G.		[ 6]
Glyburide	N.A.	Hypoglycemia	Allele A is not associated with risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele G.		[ 6]
Genetic Polymorphism	rs1799857
Site of GPD	chr11:17430945 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.5710/1130 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele A is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele G.		[ 3]
Genetic Polymorphism	rs2074315
Site of GPD	chr11:17417343 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C
Minor Allele Frequency	A=0.6130/1213 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele C is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele A.		[ 3]
References
1	CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. Eur J Clin Pharmacol. 2014 Apr;70(4):421-8.
2	The Ser1369Ala variant of ABCC8 and the risk for severe sulfonylurea-induced hypoglycemia in German patients with Type 2 diabetes. Pharmacogenomics. 2012 Jan;13(1):5-7; author reply 9-10.
3	Association of ABCC Gene Polymorphism With Susceptibility to Antituberculosis Drug-Induced Hepatotoxicity in Western Han Patients With Tuberculosis. J Clin Pharmacol. 2020 Mar;60(3):361-368.
4	Genotypic and Phenotypic Factors Influencing Drug Response in Mexican Patients With Type 2 Diabetes Mellitus. Front Pharmacol. 2018 Apr 6;9:320.
5	Pharmacogenetics of sulfonylurea-induced hypoglycemia in Type 2 diabetes patients: the SUCLINGEN study. Pharmacogenomics. 2021 Nov;22(16):1057-1068.
6	Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care. Pharmacogenomics J. 2020 Dec;20(6):831-839.
7	ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas. Pharmacogenomics. 2010 Dec;11(12):1743-50.
8	Clinical and genetic predictors of secondary sulfonylurea failure in Type 2 diabetes patients: the SUCLINGEN study. Pharmacogenomics. 2020 Jun;21(9):587-600.
9	Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. Pharmacogenomics. 2018 Feb;19(3):175-184.
10	Association of SLC22A1, SLC47A1, and KCNJ11 polymorphisms with efficacy and safety of metformin and sulfonylurea combination therapy in Egyptian patients with type 2 diabetes. Res Pharm Sci. 2023 Dec;18(6):614-625.
11	KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. Eur J Intern Med. 2012 Apr;23(3):245-9.
12	Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus. Mol Genet Metab. 2012 Mar;105(3):525-7.
13	Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabet Med. 2001 Mar;18(3):206-12.
14	Sequence variations in the human Kir6.2 gene, a subunit of the beta-cell ATP-sensitive K-channel: no association with NIDDM in while Caucasian subjects or evidence of abnormal function when expressed in vitro. Diabetologia. 1996 Oct;39(10):1233-6.
15	KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes. Clin Pharmacol Ther. 2010 Mar;87(3):330-5.
16	The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006 Jun;91(6):2334-9.
17	KCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients. Clin Exp Pharmacol Physiol. 2014 Oct;41(10):748-54.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.